The US Food and Drug Administration authorized new cardiac devices from Medtronic plc, Boston Scientific Corporation and Abbott Laboratories designed to help physicians monitor their patients remotely through mobile device apps.
Medtronic announced plans to launch the LINQ II insertable cardiac monitor in the US later this summer following 510(k)






